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Abstract: Endocrine therapy is used to treat estrogen receptor (ER)-positive breast cancer. Tamoxifen
is effective against this cancer subtype. Nonetheless, approximately 30% of patients treated with
tamoxifen acquire resistance, resulting in therapeutic challenges. NR4A1 plays key roles in processes
associated with carcinogenesis, apoptosis, DNA repair, proliferation, and inflammation. However,
the role of NR4A1 in tamoxifen-resistant ER-positive breast cancer has not yet been elucidated.
Here, we propose that NR4A1 is a promising target to overcome tamoxifen resistance. NR4A1 gene
expression was downregulated in tamoxifen-resistant MCF7 (TamR) cells compared to that in MCF7
cells. Kaplan-Meier plots were used to identify high NR4A1 expression correlated with increased
survival rates in patients with ER-positive breast cancer following tamoxifen treatment. Gain and
loss of function experiments showed that NR4A1 restores sensitivity to tamoxifen by regulating
cell proliferation, migration, invasion, and apoptosis. NR4A1 localized to the cytoplasm enhanced
the expression of apoptotic factors. In silico and in vitro analyses revealed that NR4A1 enhanced
responsiveness to tamoxifen by suppressing ERK signaling in ER-positive breast cancer, suggesting
that the NR4A1/ERK signaling axis modulates tamoxifen resistance. These results indicate that
NR4A1 could be a potential therapeutic target to overcome tamoxifen resistance in ER-positive
breast cancer.
Keywords: NR4A1; ERK signaling pathway; tamoxifen resistance; breast cancer
1. Introduction
Breast cancer is one of the most common cancers in women worldwide [1], and it can
be classified into four molecular subtypes based on gene expression profiling [2]. Among
these subtypes, estrogen receptor (ER)-positive breast cancer accounts for approximately
70% of all breast cancers and are generally treated with endocrine therapies, such as ta-
moxifen and aromatase inhibitor [3]. Tamoxifen, which is the most widely used endocrine
therapy, has significant therapeutic effects; however, approximately one-third of patients
with ER-positive breast cancer treated with tamoxifen for 5 years acquire resistance to
the drug, which reduces its therapeutic effect and shortens the survival of patients [4–6].
However, the molecular targets for predicting tamoxifen resistance are still insufficient.
Therefore, discovering molecular mechanisms and genes associated with tamoxifen resis-
tance is required to develop novel therapeutic strategies to overcome tamoxifen resistance
in patients with ER-positive breast cancer.
The NR4A subfamily, which consists of NR4A1 (Nur77), NR4A2 (Nurr1), and NR4A3
(Nor1), belongs to the orphan nuclear receptor family with members whose ligands are
unknown, which function as transcription factors [7]. NR4A subfamily members are early
response genes affected by various signals in a variety of cells and tissues and are known
to be involved in cellular activities such as proliferation, migration, apoptosis, DNA repair,
inflammation, metabolism, and angiogenesis [8,9]. These functions depend on cellular
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localization and post-translational modification as well as gene expression [10]. Among
NR4A subfamily members, the function of NR4A1 is the most known, and NR4A1 acts as an
oncogene or a tumor suppressor in diverse cancer models, such as colon cancer, liver cancer,
lung cancer, melanoma, and acute myeloid leukemia [11–15]. Especially, the loss of NR4A1
and NR4A3 in mice leads to the rapid development of lethal acute myeloid leukemia,
indicating tumor suppressor-like activity for these receptors [15–17]. Similarly, the role of
NR4A1 in breast cancer has been controversial. Recent studies have shown that ectopic
expression of NR4A1 promotes invasion and metastasis by activating TGF-β/SMAD
signaling in breast cancer [18]. Further, the translocation of NR4A1 from the nucleus to
the cytoplasm has been found to induce apoptosis in all-trans retinoic acid-induced breast
cancer cells [19]. NR4A1 also inhibits growth and metastasis in triple-negative breast
cancer [20]. However, the functional role and associated molecular mechanism of NR4A1
in tamoxifen-resistant breast cancer have not been elucidated.
The mitogen-activated protein kinase (MAPK) cascade, including extracellular signal-
regulated kinase (ERK), c-Jun NH2-terminal kinase, and p38, is a signaling pathway that
regulates various cellular functions [21] and is activated in most cancer models [22]. In
particular, several studies have suggested that the ERK signaling pathway plays impor-
tant roles in breast cancers [23]. Activation of ERK signaling in breast cancer is not only
associated with augmented tumor growth and metastasis [24,25] but also with tamoxifen
resistance [26]. Activated ERK signaling reduces the response and effectiveness of tamox-
ifen treatment and causes poor prognosis in patients with ER-positive breast cancer [27,28].
Therefore, the inhibition of ERK signaling associated with tamoxifen resistance improves
the survival rate of patients with ER-positive breast cancer because of their increased
response to tamoxifen therapy.
In this study, we explored the role and regulatory mechanism of NR4A1 in tamoxifen-
resistant ER-positive breast cancer cells and patient sample data retrieved from a public
database cBioportal. We found that NR4A1 increases responsiveness to tamoxifen, result-
ing in reduced cell growth, invasion, and migration, and induced apoptosis following
tamoxifen treatment. NR4A1, located in the cytoplasm, also enhances the expression of
apoptosis-related molecules. Mechanistically, NR4A1 re-sensitizes the response to tamox-
ifen by suppressing the ERK signaling pathway. Our results demonstrate that NR4A1
reduces tamoxifen resistance by regulating ERK signaling in ER-positive breast cancer, sug-
gesting that it could be a novel diagnostic marker and/or therapeutic target to overcome
tamoxifen resistance.
2. Materials and Methods
2.1. Cell Culture and Treatment
MCF7, T47D, tamoxifen-resistant MCF7 (TamR), and T47D (T47D-TamR) breast cancer
cells were used in this study. MCF7 cells were provided by Kyung Tae Kim (National
Cancer Center, Korea). TamR cells were established as an in vitro model for tamoxifen
resistance by treating MCF7 cells with 1 µM 4-hydroxytamoxifen (Sigma, MO, USA) for
at least 6 months [29]. T47D and T47D-TamR cells were provided by Dr. Mi-Ock Lee
(Seoul National University, Korea). MCF7 and TamR cells were cultured in Dulbecco’s
modified Eagle’s medium (WelGENE Inc., Daegu, Korea) supplemented with 10% fetal
bovine serum (WelGENE Inc., Daegu, Korea) and 1% penicillin-streptomycin (WelGENE
Inc., Daegu, Korea). T47D and T47D-TamR cells were cultured in RPMI 1640 (WelGENE
Inc., Daegu, Korea) with the same supplementation. TamR cells were cultured in a medium
containing 1 µM 4-hydroxytamoxifen (Sigma, MO, USA). Cells were grown at 37 ◦C in
a 5% CO2 incubator. For some experiments, NR4A1-knockdown cells were treated with
50 µM ERK1/2 inhibitor U0126 (Calbiochem, CA, USA) for 2 h prior to analysis.
2.2. Plasmid and siRNA Transfection
For the overexpression study, the full-length coding sequence of the NR4A1 gene
was cloned into a pcDNA3-HA-tagged vector, and 7.5 × 105 cells were transfected with
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pcDNA3-NR4A1 plasmid for 24 h using Attractene (Qiagen, Hilden, Germany) according
to the manufacturer’s protocol. To generate stable cell lines, pcDNA3-NR4A1 plasmid-
transfected cells were treated with 500 µg/mL G418 for 2 weeks. For the knockdown
study, 3.5 × 105 cells were transfected with 50 nM of NR4A1-siRNA (Genolution, Seoul,
Korea) or control siRNA (Genolution, Seoul, Korea) for 48 h using G-fectin (Genolu-
tion, Seoul, Korea) following the manufacturer’s protocol. siRNAs were designed and
purchased from Genolution. The sequence of siRNA was as follows: siNR4A1 #1: Sense—5′-
GCUACACAGGAGAGUUUGAUU-3′, Antisense—5′-UCAAACUCUCCUGUGUAGCUU-
3′; siNR4A1 #2: Sense—5′-GAAGUUGUCCGAACAGACAUU-3′, Antisense—5′-UGUCUG
UUCGGACAACUUCUU-3′.
2.3. Total RNA Isolation and Quantitative Real-Time PCR
Total RNA was extracted from cells using TRIzol reagent (Invitrogen, CA, USA) fol-
lowing the manufacturer’s instructions. cDNA was synthesized from 1 µg of total RNA
by reverse transcription using ImProm-II Reverse Transcriptase (Promega, WI, USA). PCR
was performed using Taq DNA polymerase (Bioneer, Seongnam, Korea) with the following
conditions: initial denaturation for 5 min at 95 ◦C, followed by 28–36 cycles at 95 ◦C for
40 s, at 56 ◦C for 20 s (depending on target genes), and at 72 ◦C for 30 s. For quantitative
real-time PCR, Power SYBR Green PCR Master Mix (Applied Biosystems, CA, USA) and
StepOnePlusTM Real-Time PCR System (Applied Biosystems, San Francisco, CA, USA)
were used. All PCR reactions were performed at least in triplicate, and gene expression
was normalized relative to that of human β-Actin and GAPDH, which were used as
internal controls. Primers used for PCR were as follows: Human NR4A1: Forward—5′-
CCAAGTACATCTGCCTGGCTA-3′, Reverse—5′-GACAACTTCCTTCACCATGCC-3′; Hu-
man NR4A2: Forward—5′- CCCAGTGGAGGGTAAACTCAT-3′, Reverse—5′- TGTCTCT
CTGTGACCATAGCC-3′; Human NR4A3: Forward—5′- CTTTGCAACGCTGACGGTG-
3′, Reverse—5′-CGACTCATGGGAGAGCACAG-3′; Human SERPINE1: Forward—5′-
GGAGAAACCCAGCAGCAGATT-3′, Reverse—5′-CTGTGGTGCTGATCTCATCCTT-3′;
Human STAT1: Forward—5′-GCACGCTGCCAATGATGTTT-3′, Reverse—5′-ACATCTGG
ATTGGGTCTTCCTG-3′; Human ELK1: Forward—5′-CTTCACGGGATGGTGGTGAA-3′,
Reverse—5′-CCGGCTGAGCTTGTCGTAAT-3′; Human JUNB: Forward—5′-CCCTACCGG
AGTCTCAAAGC-3′, Reverse—5′-TGCTGTTGGGGACAATCAGG-3′; Human DUSP1:
Forward—5′-TCCCAACCATTTTGAGGGTCA-3′, Reverse—5′-AAACACCCTTCCTCCAG
CATT-3′; Human FOS: Forward—5′-TTACTACCACTCACCCGCAG-3′, Reverse—5′-GCAG
TGACCGTGGGAATGAA-3′; Human GAPDH: Forward—5′-TATAAATTGAGCCCGCAGC
C-3′, Reverse—5′-CCCAATACGACCAAATCCGTTG-3′; and Human β-actin: Forward—5′-
CATGTTTGAGACCTTCAACACCCC-3′, Reverse—5′-GCCATCTCCTGCTCGAAGTCTAG-3′.
2.4. Cell Proliferation Assay
Cell proliferation assay was performed using Cell Counting Kit-8 (CCK-8; Dojindo
Molecular Technologies Inc., Kumamoto, Japan) according to the manufacturer’s protocol.
Briefly, 7.5× 103 cells per well were seeded on 96-well plates and cultured in media with or
without 8 µM tamoxifen. The cells were stained with 10 µL of 2-(2-methoxy-4-nitrophenyl)-
3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-8), for 3 h
at 37 ◦C in a 5% CO2 incubator on designated days. Absorbance was measured using an
ELISA reader (Softmax Pro., Molecular Devices, San Jose, CA, USA) at 450 nm. Tamoxifen
treatment was refreshed every 24 h to maintain a constant concentration.
2.5. Spheroid Formation Assay
Spheroid cultures were performed according to the previous procedure with minor
changes [30]. Briefly, 1 × 104 cells/mL were counted and resuspended carefully using a
25 G syringe needle to obtain a single-cell suspension. The cells were pelleted, washed
with cold PBS, and syringe-filtered again to ensure a single-cell suspension. Cells were
plated onto Ultra-Low attachment 6-well plates (Corning, NY, USA) with 2 mL DMEM/F12
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media (WelGENE Inc., Daegu, Korea) supplemented with 1% PSA, 2% B27, 10 ng/mL
FGFb, 20 ng/mL EGF, 5 µg/mL insulin, and 4 µg/mL heparin. Cells were maintained at
37 ◦C in a 5% CO2 incubator on designated days. The number of spheroids with a diameter
greater than 50 µm was regularly counted.
2.6. Invasion and Migration Assays
Invasion assay was performed using MatrigelTM (BD, Franklin Lakes, NJ, USA), as
previously described [31], while migration assay was carried out using the same method in
the absence of MatrigelTM. Approximately 5 × 104 cells were seeded in each chamber and
incubated at 37 ◦C for 48 h. Invasive and migrating cells were stained with fluorochrome
4′,6-diamidino-2-phenylindole (DAPI), and observed via fluorescence microscopy. The
acquired images were analyzed using the ImageJ software.
2.7. Apoptosis Assay by Annexin V-FITC/Propidium Iodide (PI) Staining
Apoptotic cells were determined using the EzWayTM Annexin V-FITC (Komabiotech,
Seoul, Korea) apoptosis detection kit. Approximately 5 × 105 cells were seeded and
incubated for 24 h with 15 µM tamoxifen. Subsequently, the cells were harvested, washed
with cold PBS, and stained with Annexin V-FITC and PI. Stained cells were analyzed using
BD FACS LSRII (BD Biosciences, San Jose, CA, USA), and data were acquired using BD
FACSDivaTM software.
2.8. Nuclear and Cytoplasmic Protein Fractionation
For nuclear and cytoplasmic protein fractionation, cells were lysed in cold buffer A
(10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, protease inhibitor) for
5 min on ice. NP-40 was then added to give a final concentration of 0.6%. The cytoplasmic
protein of the total cell lysate was obtained by centrifugation for 30 s at 4 ◦C. The nuclear
cell pellet was washed with cold PBS and lysed in cold buffer C (20 mM HEPES, pH 7.9,
0.4 M NaCl, 1 mM EDTA, 1 mM DTT, protease inhibitor) for 15 min on ice. Nuclear proteins
were harvested by centrifugation for 15 min at 4 ◦C, and protein extracts were analyzed
using western blotting.
2.9. Immunocytochemisty
For immunocytochemistry, cells were fixed with 4% paraformaldehyde in PBS for
15 min and rinsed with cold PBS. Cell permeabilization was performed using 0.25% Triton
X-100 in PBS for 10 min. The cells were then blocked with 5% bovine serum albumin
for 1 h. After blocking, cells were incubated with primary antibody against NR4A1
(Abcam, ab13851, Cambridge, UK) at 4 ◦C overnight. The cells were subsequently washed
with PBS and incubated with goat anti-rabbit IgG Alexa Fluor 594 (Abcam, ab150080,
Cambridge, UK) for 1 h in the dark. DAPI was added to the cells, which were then
incubated for 20 min. Fluorescence images were acquired using a Zeiss LSM 700 confocal
microscope (Carl Zeiss, Jena, Germany).
2.10. Western Blot Analysis
All breast cancer cell lines were treated under the appropriate conditions and lysed
in NP-40 lysis buffer, after which their protein concentrations were estimated using the
Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Each lysate was
separated by 8–12% SDS polyacrylamide gel electrophoresis and then transferred to
Immobilon-P PVDF transfer membranes (Merck Millipore, Burlington, MA, USA). Im-
munoreactive bands were detected using suitable primary antibodies and the appropriate
HRP–conjugated secondary antibodies. Bands were visualized using the SuperSignal West
Pico Chemiluminescent Substrate Kit (Thermo Scientific, Waltham, MA, USA). Anti-NR4A1
(ab13851, Abcam, Cambridge, UK), anti-Caspase-7 (#12827, Cell Signaling Technology, Dan-
vers, MA, USA), anti-Caspase-9 (#9508, Cell Signaling), anti-PARP (#9542, Cell Signaling),
anti-Src (#2110, Cell Signaling), anti-phospho-Src (#6943, Cell Signaling), anti-MEK1/2
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(#4694, Cell Signaling), anti-phospho-MEK1/2 (#9154, Cell Signaling), anti-ERK1/2 (#9102,
Cell Signaling), anti-phospho-ERK1/2 (#9101, Cell Signaling), anti-HDAC1 (ab7028, Ab-
cam), and anti-β-actin (ab6276, Abcam) were used to detect proteins.
2.11. In Silico Analysis
2.11.1. Gene Expression Omnibus (GEO) Dataset
The GEO dataset (GSE1378) obtained from the GEO database (http://www.ncbi.nlm.
nih.gov/geo (accessed on 18 June 2021)) was used to assess NR4A1 mRNA levels in luminal
A type breast cancer cohorts treated with tamoxifen monotherapy.
2.11.2. Kaplan-Meier Survival Analysis
The Kaplan-Meier plotter (http://www.kmplot.com (accessed on 18 June 2021)) was
used to assess the effect of genes on the survival rate of human breast cancer samples. To
investigate the prognostic value of NR4A family genes, patient samples were classified
into low- and high-expression groups using median as the cutoff value.
2.11.3. cBioportal
The web-available database cBioportal (http://www.cbioportal.org (accessed on
18 June 2021)) was used to evaluate the molecular profile changes of NR4A1 in breast
cancer tissues. Patient sample data were obtained from the Breast Invasive Carcinoma
(TCGA, Nature 2012).
2.11.4. Gene Ontology Functional Enrichment Analysis
Gene ontology functional enrichment analysis was performed for differentially ex-
pressed genes (DEGs) according to NR4A1 mRNA levels using the DAVID database
(version DAVID 6.8; http://david.ncifcrf.gov (accessed on 18 June 2021)) to annotate bio-
logical processes. Both upregulated and downregulated DEGs were used, and statistical
significance was set at p < 0.01.
2.11.5. Gene Set Enrichment Analysis (GSEA)
GSEA was performed to evaluate potential gene sets and pathways enriched in
breast cancer tissue samples with high and low expression of NR4A1 obtained from the
cBioportal database. The GSEA software was installed from the Broad Institute online web-
site (https://www.gsea-msigdb.org/gsea/msigdb/index.jsp (accessed on 18 June 2021)).
The enriched gene sets with a p-value < 0.05 and FDR q-value < 0.05 were considered
statistically significant.
2.12. Statistical Analysis
Data are expressed as the mean ± standard error of the mean of at least three different
experiments. Statistical differences were determined using the paired Student’s t-test.
Statistical significance was set at p < 0.05.
3. Results
3.1. NR4A1 Is Associated with Tamoxifen Sensitivity in ER-Positive Breast Cancer
To investigate NR4A1 gene expression in tamoxifen-resistant (TamR) breast cancer
cells, we examined the mRNA and protein expression levels of NR4A1 in MCF7 and TamR
cells using qRT-PCR and western blotting. Our results showed that the mRNA and protein
levels of NR4A1 were significantly downregulated in TamR cells compared to those in
MCF7 and T47D cells (Figure 1A,B and Figure S1A,B). We also compared the expression
of NR4A1 in clinical breast cancer patient samples retrieved from a publicly available
dataset (GSE1378, METABRIC). The expression levels of NR4A1 decreased in patients
with recurred (tamoxifen-resistant) luminal A type breast cancer treated with tamoxifen
therapy (GSE1378) and hormone therapy (METABRIC) compared to those in patients with
non-recurred (tamoxifen-sensitive) luminal A type breast cancer (Figure 1C,D).
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Figure 1. NR4A1 is associated with tamoxifen sensitivity in ER-positive breast cancer. mRNA (A) and protein (B) expression
levels of NR4A1 in MCF7 and TamR breast cancer cells from two different passages. (C) The mRNA expression levels
of NR4A1 in patients with luminal A type breast cancer and recurred patients treated with tamoxifen monotherapy for
5 years (GSE1378) (n = 52, p = 0.04) are shown using log2 expression values. (D) The mRNA expression levels of NR4A1
in patients with ER-positive breast cancer and recurred patients treated with hormone therapy (METABRIC) (n = 1079,
p = 9.585 × 10−4) are shown using log2 expression values. Data was retrieved from cBioportal. (E) Kaplan-Meier analysis
curves of overall survival (OS; upper panel) (n = 250, p = 0.42) and recurrence-free survival (RFS; lower panel) (n = 503,
p = 0.55) rates of patients with ER-positive breast cancer receiving no treatment. (F) Kaplan-Meier analysis curves of OS
(upper panel; n = 130, p = 0.047) and RFS (lower panel; n = 740, p = 0.0095) rates of patients with ER-positive breast cancer
following tamoxifen therapy. The NR4A1 (211143_x_at) probe was used and analyzed to detect survival rates. * p < 0.05 and
*** p < 0.001.
Further, we examined whether the elevated NR4A1 expression was associated with an
increased survival rate in human breast cancer using NR4A1 gene expression. To assess the
clinical relevance between NR4A1 expression and survival rate, we analyzed the survival
of patients with ER-positive breast cancer using Kaplan-Meier survival analysis. High
expression of NR4A1 correlated with good overall survival (OS) and relapse-free survival
(RFS) in patients with ER-positive breast cancer following tamoxifen therapy, although
there was no significant association in untreated patients (Figure 1E,F). The NR4A family
genes NR4A2 and NR4A3 showed no significant difference between the mRNA levels
of MCF7 and TamR cells, although high NR4A3 level represented favorable OS and RFS
Cells 2021, 10, 1633 7 of 15
in patients treated with tamoxifen therapy, but not NR4A2 level (Figure S2A–F). Taken
together, these results show that NR4A1 is associated with tamoxifen sensitivity in human
ER-positive breast cancer.
3.2. NR4A1 Suppresses Proliferation, Migration, and Invasion Ability, While Increasing
Ttamoxifen-Induced Apoptosis in TamR Cells
To confirm tamoxifen resistance in our cell line, we compared cell proliferation be-
tween MCF7 and TamR cells using the CCK-8 assay. TamR cells were resistant to tamoxifen
treatment (Figure S3A). To investigate the functional role of NR4A1 in TamR cells, we
confirmed the ectopic overexpression of NR4A1 in TamR cells and knockdown of NR4A1
in MCF7 cells via RT-PCR and western blot (Figure 2A and Figure S4). There was no
difference in cell proliferation when NR4A1 was knocked down in MCF7 cells in the
absence of tamoxifen (No Tam.). Interestingly, NR4A1 knockdown increased tamoxifen
resistance in MCF7 cells treated with tamoxifen for 4 days (Figure 2B). Consistent with the
results of NR4A1 knockdown, overexpression of NR4A1 significantly restored sensitivity to
tamoxifen in TamR cells (Figure 2C). These results suggest that NR4A1 expression regulates
tamoxifen sensitivity in ER-positive breast cancer cells.
We compared tumor formation ability using 3-D spheroid formation assay to mimic
the characteristics of human tumors. We confirmed that TamR cells represent higher
spheroid formation ability compared to MCF7 cells (Figure S3B). To confirm that this
spheroid formation was due to the expression of NR4A1 in ER-positive breast cancer cells,
NR4A1-depleted MCF7 cells and NR4A1-overexpressing TamR cells were used to assess the
spheroid formation abilities. A significant increase of spheroid in NR4A1 knockdown MCF7
cells compared to control cells was examined, and overexpression of NR4A1 significantly
inhibited the size of spheroid in TamR cells (Figure 2D). These results showed that NR4A1
expression significantly suppressed solid tumor-like properties in ER-positive breast cancer.
Because tamoxifen-resistant breast cancer cells have migratory and invasive proper-
ties [32], we confirmed that TamR cells exhibit higher migratory and invasive abilities than
those of MCF7 cells through transwell migration and invasion assays (Figure S3C). We
then evaluated the effect of NR4A1 expression on the migration and invasion abilities of
TamR cells. As shown in Figure 2E, NR4A1 overexpression significantly reduced these
abilities in TamR cells.
Since it is known that NR4A1 induces cell apoptosis in several tumor types [33],
we investigated whether the expression of NR4A1 re-sensitizes TamR cells to tamoxifen
treatment by increasing apoptotic ability. Flow cytometry analysis was performed using
annexin V/PI staining to compare the apoptotic levels between MCF7 and TamR cells in the
absence and presence of tamoxifen. High-dose tamoxifen (15 µM) treatment induced apop-
tosis in MCF7 cells, while there were insignificant changes in TamR cells (Figure S3D,E). In
addition, overexpression of NR4A1 in TamR cells (TamR-NR4A1) significantly increased
the percentage of apoptotic cell death compared to that in control cells (TamR-vec) when ta-
moxifen was added (Figure 2F,G). These results demonstrated that NR4A1 overexpression
enhanced tamoxifen-induced apoptotic ability of tamoxifen-resistant ER-positive breast
cancer cells. Thus, NR4A1 inhibits cell proliferation, migration, and invasion ability, while
enhancing tamoxifen-induced apoptosis in TamR cells.
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Figure 2. NR4A1 suppresses proliferation, migration, and invasion, while increasing tamoxifen-induced apoptosis in TamR
cells. (A) mRNA expression levels of NR4A1 in MCF7, TamR, MCF7 cells transfected with siControl (siCon) or NR4A1
siRNA (siNR4A1), and TamR cells transfected with pcDNA3 (empty vector) or pcDNA3-NR4A1. (B) Cell proliferation
curves of siCon/siNR4A1 MCF7 cells untreated (No Tam.) or treated with 10 µM tamoxifen (Tam.) for 4 days. (C) Cell
proliferation curves of TamR-vec and TamR-NR4A1 cells untreated (No Tam.) or treated with 10 µM tamoxifen (Tam.) for
5 days. (D) Representative images of breast cancer spheroids growth of MCF7 cells transfected with siCon or siNR4A1, and
TamR cells transfected with empty vector or pcDNA3-NR4A1 (left panel). Spheroid formation was analyzed after 6 days.
Quantification of average spheroid diameter (right panel) is represented on a bar graph. (E) Matrigel invasion and migration
assays in empty vector transfected TamR and stable NR4A1-overexpressing TamR cells. Migrating and invasive cells stained
with DAPI were calculated using imageJ. (F) FACS analysis of apoptotic cell death in TamR-vec and TamR-NR4A1 cells
untreated or treated with 15 µM tamoxifen. Apoptotic cells were stained by Annexin V/PI. (G) Percentage of apoptotic cells
from (F) are represented on a bar graph. * p < 0.05, ** p < 0.01, and *** p < 0.001.
3.3. NR4A1 Localized in the Cytoplasm Affects Apoptosis
Since NR4A1 has different functions depending on subcellular localization in various
types of cancer model [34], we compared the distribution and subcellular localization of
NR4A1 between MCF7 and TamR cells by nuclear and cytoplasmic fractionation. Our
results showed that NR4A1 is primarily localized in the cytoplasm in both cells and
up-regulated in MCF7 than TamR cells (Figure 3A). Immunocytochemistry analysis also
revealed that NR4A1 predominantly localizes in the cytoplasm of MCF7 cells (Figure 3B).
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Although NR4A1 also existed slightly in the nuclear fraction, we focused on the cyto-
plasm, as NR4A1 was more abundant in the cytoplasm. It has been reported that NR4A1,
which translocates from the nucleus to the cytoplasm, releases cytochrome c and induces
apoptosis [35]. Thus, we hypothesized that high expression of cytoplasmic NR4A1 in
MCF7 cells might cause apoptosis and explored the expression of pro-apoptotic genes
by western blotting. Results showed that the protein levels of cleaved caspase-7, -9, and
PARP, and uncleaved PARP were higher in MCF7 cells than in TamR cells. When NR4A1
was knocked down in MCF7 cells, the levels of cleaved caspase-7, cleaved PARP, and un-
cleaved PARP decreased, while the level of cleaved caspase-9 did not change. Conversely,
when NR4A1 was overexpressed in TamR, the cleaved forms of caspase-7, -9, and PARP
increased, although the uncleaved forms did not change (Figure 3C). Additionally, we
performed immunocytochemistry to confirm the subcellular localization of NR4A1 when
NR4A1 was overexpressed in TamR and found that NR4A1 was mainly distributed in the
cytoplasm (Figure S5). These results confirmed that NR4A1 localized in the cytoplasm
plays an essential role in inducing the expression of apoptosis-related factors.
Figure 3. NR4A1 localized in the cytoplasm influences apoptosis. (A) Western blot analysis of cytoplasmic and nuclear
NR4A1 proteins in MCF7 and TamR cells. (B) Representative images of immunofluorescence for NR4A1 localization in
MCF7 and TamR cells. Scale bar = 100 µm. (C) Western blot analysis for apoptosis-related proteins in MCF7, TamR, MCF7
cells transfected with scramble (negative) control (siCon), NR4A1 siRNA (siNR4A1), and TamR cells transfected with
pcDNA3 and pcDNA3-NR4A1.
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3.4. NR4A1 Alters Tamoxifen Sensitivity in ER-Positive Breast Cancer Cells by Suppressing ERK
Signaling Pathway
To investigate the molecular mechanism by which NR4A1 regulates tamoxifen sen-
sitivity, we performed gene expression profiling using the breast cancer patient dataset
retrieved from cBioportal. We ultimately identified 199 DEGs according to NR4A1 mRNA
levels (Figure 4A). To determine the biological function of the target genes, DEGs were
subjected to gene ontology functional enrichment analysis using the DAVID database.
Results showed that these NR4A1 target genes were significantly enriched in the negative
regulation of ERK1 and ERK2 cascade (Figure 4B). Moreover, GSEA conducted between
the NR4A1 high and low groups revealed that high mRNA levels of NR4A1 are correlated
with the negative regulation of MAPK cascade (Figure S6A,B). Furthermore, previous
studies have reported that cytoplasmic NR4A1 is associated with ERK signaling and a
good prognosis [36]. This evidence raises the possibility that NR4A1 genes may contribute
to the negative regulation of the ERK signaling pathway in breast cancer. Therefore, we
examined the expression levels of proteins related to the ERK signaling pathway. First,
the results demonstrated that the protein levels of p-SRC, p-MEK1/2, and p-ERK1/2 were
higher in TamR cells than in MCF7 cells. In addition, western blot analysis confirmed that
NR4A1 could downregulate the levels of p-SRC, p-MEK1/2, and p-ERK1/2 (Figure 4C).
Because NR4A1 changes the level of phosphorylated ERK protein, which is functional, we
assumed that NR4A1 would also change the expression of target genes that are directly
regulated by ERK. Therefore, the transcription levels of several ERK target genes were
confirmed by quantitative real-time PCR. Results showed that ERK target genes such as
STAT1 and DUSP1 were also regulated according to the expression of NR4A1 (Figure 4D).
The ERK signaling pathway is known to play an important role in the tamoxifen-resistant
phenotype [26]. To evaluate whether the induction of ERK signaling is necessary for
silenced-NR4A1-mediated tamoxifen resistance, we treated MCF7-siNR4A1 cells with
U0126, an ERK1/2 inhibitor, and performed CCK-8 assay. Results showed that U0126
could reverse the ability of cell proliferation, which was enhanced by NR4A1 knockdown
(Figure 4E). Additionally, we measured the expression level of p-ERK1/2 after treatment
with U0126. As shown in Figure 4F, the inhibitor treatment efficiently inhibited the phospho-
rylation of ERK1/2, which was increased following NR4A1 knockdown without affecting
the total ERK1/2 level. Taken together, our data suggest that NR4A1 regulates tamoxifen
sensitivity by inhibiting the ERK signaling pathway in ER-positive breast cancer.
Cells 2021, 10, 1633 11 of 15
Figure 4. NR4A1 alters tamoxifen sensitivity in ER-positive breast cancer cells by suppressing the ERK signaling pathway.
(A) The volcano plot of significantly up- and down-regulated genes according to mRNA expression profile of NR4A1 gene
(Student’s t-test p < 0.05 and Benjamini-Hochberg procedure q < 0.05). (B) Gene ontology functional enrichment analysis
showing biological processes enriched in 199 genes regulated by NR4A1. (C) Western blot analysis of ERK signaling
pathway-related protein in MCF7, TamR, MCF7 cells transfected with scramble (negative) control (siCon), NR4A1 siRNA
(siNR4A1), and TamR cells transfected with pcDNA3 and pcDNA3-NR4A1. (D) mRNA expression levels of ERK target
genes in MCF7 cells transfected with scramble (negative) control (siCon) and NR4A1 siRNA (siNR4A1), and TamR cells
transfected with pcDNA3 and pcDNA3-NR4A1. (E) Western blot analysis of NR4A1, ERK1/2, and p-ERK1/2 proteins
in MCF7-siCon and siNR4A1 cells following treatment with U0126 or DMSO (control) (F) Cell proliferation curves of
MCF7-siCon and siNR4A1 cells treated with U0126 or DMSO (control) under the presence of 8 µM tamoxifen (Tam.) for
4 days. *** p < 0.001.
4. Discussion
Here, we demonstrated that NR4A1, whose expression was downregulated in TamR
cells and patients with recurrent breast cancer treated with tamoxifen, may be a new prog-
nostic factor and therapeutic target for tamoxifen resistance. In our Kaplan-Meier analysis,
we found that high expression of NR4A1 in patients with ER-positive breast cancer treated
with tamoxifen associates with a good prognosis. Through gain- and loss-of-function study,
the subsequent upregulation of NR4A1 expression enhanced tamoxifen sensitivity, thereby
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regulating cell proliferation, migration, invasion, and apoptosis in tamoxifen-resistant
cells. More importantly, high cytoplasmic NR4A1 contributes to apoptosis by inducing
the expression of pro-apoptotic factors in breast cancer cells. Mechanistically, we revealed
that NR4A1 restored tamoxifen sensitivity by inhibiting the ERK signaling pathway in
tamoxifen-resistant breast cancer cells.
NR4A1 is an early response gene promptly induced by various cellular stimuli and
plays an important role in various physiological processes and diseases, including cancer [9].
Several studies have shown that NR4A1 promotes or inhibits tumor progression depending
on the tumor type, cell-specific context, and various external stimuli. NR4A1 expression
has been previously reported to be upregulated in non-small-cell lung carcinoma tissues
compared to that in normal tissues, and high NR4A1 level has shown an oncogenic role
as a prognostic marker for predicting adverse clinical outcomes in non-small-cell lung
carcinoma [37]. Additionally, NR4A1 expression suppresses cancer growth and progression
in triple-negative breast cancer (TNBC) in vitro and in vivo, showing its role as a tumor
suppressor [20]. Moreover, recent studies have shown that NR4A1 induces TNFα-mediated
apoptosis sensitivity in human gastric cancer [38] and improves cisplatin resistance in
ovarian cancer [39], supporting that NR4A1 plays a crucial role in drug therapy sensitivity
in a variety of tumor models. Nevertheless, the exact role of NR4A1 in tamoxifen resistance
in breast cancer has not been elucidated. In the present study, high levels of NR4A1 were
found to be associated with a favorable prognosis and tamoxifen sensitivity in patients
with ER-positive breast cancer treated with tamoxifen. Moreover, tamoxifen-resistant
cell line (TamR) used in this study showed downregulated NR4A1 expression, whereas
other NR4A factors, NR4A2 and NR4A3, did not differ in expression between MCF7 and
TamR cells. Overexpression of NR4A1 restored the sensitivity to tamoxifen and attenuated
proliferation, migration, and invasion; however, it enhanced tamoxifen-induced apoptosis
in TamR cells. This phenomenon has also been observed in previous studies that NR4A1
reduces migration in both normal and breast cancer cells [40] and mediates apoptosis in
aggressive B-cell lymphoma [33], indicating that NR4A1, which regulates cellular processes
in response to tamoxifen, could suppress the acquisition of a tamoxifen-resistant phenotype.
Thus, NR4A1 could prove useful as a predictor of tamoxifen responsiveness and therapeutic
target to overcome tamoxifen resistance in ER-positive breast cancer.
Localization of NR4A1 protein in the cell is crucial for understanding its biological
effects, and subcellular mislocalization of proteins can work as a molecular therapeutic
intervention [41]. The function of NR4A1 is influenced not only by expression but also
by its localization within the cell. NR4A1 present in the nucleus is translocated to the
cytoplasm in response to several apoptosis-inducing agents, where it binds to Bcl-2 and
forms a pro-apoptotic complex, inducing cytochrome c release and cell apoptosis through a
p53-independent intrinsic pathway [35]. In this study, surprisingly, we found that NR4A1 is
mainly located in the cytoplasm of both MCF7 and TamR breast cancer cells and promoted
the expression of apoptosis-related molecules, including caspase-7, caspase-9, and PARP.
Similarly, several studies have also shown that NR4A1 in the cytoplasm induces apopto-
sis mediated by apoptotic-associated molecules [38,42]. Hence, its reduced expression in
tamoxifen-resistant tumor cells may contribute to apoptosis and cell survival, and transloca-
tion of NR4A1 to the cytoplasm from the nucleus by various agents, including cytosporone
B and C-DIM [43,44] may serve as a unique therapeutic strategy. However, it is still unclear
whether nuclear localization of NR4A1 through drugs that block nuclear export of NR4A1
confers tamoxifen resistance or tumor progression, thus requiring further investigation.
According to previous reports, cytoplasmic NR4A1 is associated with the ERK sig-
naling pathway [36]. ERK signaling is a pathway that plays a crucial role in tamoxifen
resistance as well as cellular signaling in various cancers, including breast cancer [26]. In
addition, activated ERK signaling reduces responsiveness and effectiveness of tamoxifen
treatment in patients with ER-positive breast cancer and affects poor prognosis [27,28].
These studies suggest that ERK acts as a prognostic marker and can serve as an indicator
of the effectiveness of tamoxifen treatment in breast cancer patients.
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In the present study, through in silico gene functional analysis and in vitro experi-
ments, we showed that NR4A1 not only reduces the expression of factors related to ERK
signaling but also regulates the mRNA expression of ERK downstream target genes (STAT1
and DUSP1), implying that ERK signaling may represent a general target pathway of
NR4A1. We further confirmed that the enhanced proliferation ability induced by NR4A1
knockdown is greatly impaired after treatment with an ERK inhibitor. Similarly, a previous
study reported that NR4A1 mitigates the level of active ERK1/2 and ERK inhibition follow-
ing U0126 treatment in NR4A1-overexpressing normal breast epithelial cells suppresses
cell migration [40]. These results support our hypothesis that deactivation of the ERK
signaling pathway is responsible for NR4A1-induced tamoxifen sensitivity. Accordingly,
the regulation of ERK signaling by NR4A1 revealed in this study is a potential therapeutic
target as well as a biomarker for treating tamoxifen resistance.
Our study is the first to reveal that NR4A1 is a marker associated with tamoxifen
sensitivity. In this study, NR4A1 induced sensitivity to tamoxifen by regulating cell prolif-
eration, migration, invasion, and apoptosis in ER-positive breast cancer cells. In addition,
translocation of NR4A1 to the cytoplasm from the nucleus localized in the cytoplasm
activated apoptotic molecules. Further, NR4A1 inhibited the ERK signaling cascade, which
in turn regulated ERK target genes, resulting in attenuated tamoxifen resistance in TamR
cells. Collectively, we have shown that NR4A1 is a crucial mediator of apoptosis depending
on their cellular location. our study suggests the NR4A1/ERK signaling axis plays an
important role in overcoming tamoxifen resistance and could be a novel therapeutic target
for attenuating tamoxifen resistance in patients with ER-positive breast cancer.
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